Multi-modality: A new approach for the treatment of major depressive disorder

Elliott Richelson

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Effective treatment with antidepressants is currently limited by factors that affect treatment compliance, including delay in onset of therapeutic effects and intolerable side-effects. Recent data suggest that use of antidepressant combinations with different mechanisms of action may be a better first-line strategy prior to augmentation with other drug classes. The rationale for this approach is that combining multiple pharmacological actions affecting multiple monoamine targets produces greater efficacy. Several new multi-modal compounds are in development and early results for the most advanced agents indicate shorter onset of therapeutic effects and improved tolerability. By modulating multiple receptors and transmitter systems, it is hoped that these new agents may also treat some of the associated symptoms of major depressive disorder, such as anxiety and cognitive dysfunction.

Original languageEnglish (US)
Pages (from-to)1433-1442
Number of pages10
JournalInternational Journal of Neuropsychopharmacology
Issue number6
StatePublished - Jul 2013


  • Antidepressant
  • MDD
  • brexpiprazole
  • multi-modal therapy
  • vilazodone
  • vortioxetine

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Multi-modality: A new approach for the treatment of major depressive disorder'. Together they form a unique fingerprint.

Cite this